Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.
Antiretroviral therapy
HIV
Molecular epidemiology
Pooled sequence analysis
Pre-treatment drug resistance
South Africa
Surveillance
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
10
09
2018
revised:
01
03
2019
accepted:
05
03
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
31
5
2019
Statut:
epublish
Résumé
South Africa has the largest public antiretroviral therapy (ART) programme in the world. We assessed temporal trends in pretreatment HIV-1 drug resistance (PDR) in ART-naïve adults from South Africa. We included datasets from studies conducted between 2000 and 2016, with HIV-1 We identified 38 datasets, and retrieved 6880 HIV-1 Increasing PDR in South Africa presents a threat to the efforts to end the HIV/AIDS epidemic. These findings support the recent decision to modify the standard first-line ART regimen, but also highlights the need for broader public health action to prevent the further emergence and transmission of drug-resistant HIV. This research project was funded by the South African Medical Research Council (MRC) with funds from National Treasury under its Economic Competitiveness and Support Package. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of CDC.
Sections du résumé
BACKGROUND
BACKGROUND
South Africa has the largest public antiretroviral therapy (ART) programme in the world. We assessed temporal trends in pretreatment HIV-1 drug resistance (PDR) in ART-naïve adults from South Africa.
METHODS
METHODS
We included datasets from studies conducted between 2000 and 2016, with HIV-1
FINDINGS
RESULTS
We identified 38 datasets, and retrieved 6880 HIV-1
INTERPRETATION
CONCLUSIONS
Increasing PDR in South Africa presents a threat to the efforts to end the HIV/AIDS epidemic. These findings support the recent decision to modify the standard first-line ART regimen, but also highlights the need for broader public health action to prevent the further emergence and transmission of drug-resistant HIV.
SOURCE OF FUNDING
BACKGROUND
This research project was funded by the South African Medical Research Council (MRC) with funds from National Treasury under its Economic Competitiveness and Support Package.
DISCLAIMER
CONCLUSIONS
The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of CDC.
Identifiants
pubmed: 31143879
doi: 10.1016/j.eclinm.2019.03.006
pii: S2589-5370(19)30042-2
pmc: PMC6510720
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26-34Subventions
Organisme : NIAID NIH HHS
ID : R24 AI136618
Pays : United States
Références
AIDS Res Hum Retroviruses. 2002 May 20;18(8):605-10
pubmed: 12036490
J Virol. 2003 Feb;77(4):2587-99
pubmed: 12551997
AIDS Res Hum Retroviruses. 2005 Jan;21(1):103-9
pubmed: 15665650
AIDS Res Hum Retroviruses. 2006 Dec;22(12):1306-12
pubmed: 17209775
J Infect Dis. 2007 Mar 1;195(5):711-5
pubmed: 17262714
Mol Biol Evol. 2007 Apr;24(4):1025-31
pubmed: 17272680
Antivir Ther. 2008;13 Suppl 2:101-7
pubmed: 18575198
AIDS Res Hum Retroviruses. 2008 Jul;24(7):1009-12
pubmed: 18593350
J Virol. 2008 Sep;82(17):8548-59
pubmed: 18596105
Clin Infect Dis. 2009 Feb 15;48(4):462-72
pubmed: 19133804
PLoS One. 2009;4(3):e4724
pubmed: 19266092
Bioinformatics. 2009 May 1;25(9):1197-8
pubmed: 19304876
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Virology. 2010 Jan 20;396(2):213-25
pubmed: 19913270
Antivir Ther. 2009;14(7):975-84
pubmed: 19918101
AIDS Res Hum Retroviruses. 2010 Jun;26(6):705-9
pubmed: 20509797
Lancet Infect Dis. 2011 May;11(5):363-71
pubmed: 21354861
J Med Virol. 2011 Sep;83(9):1508-13
pubmed: 21739439
Lancet Infect Dis. 2011 Oct;11(10):750-9
pubmed: 21802367
S Afr Med J. 2011 May;101(5):335-7
pubmed: 21837878
J Health Popul Nutr. 2011 Aug;29(4):303-9
pubmed: 21957668
Lancet Infect Dis. 2012 Apr;12(4):307-17
pubmed: 22036233
Arch Virol. 2012 Mar;157(3):455-65
pubmed: 22189822
AIDS Res Hum Retroviruses. 2012 Jun;28(6):558-65
pubmed: 22251009
Clin Infect Dis. 2012 May;54 Suppl 4:S334-8
pubmed: 22544199
J Med Virol. 2012 Dec;84(12):1839-43
pubmed: 23080485
PLoS One. 2013 Apr 09;8(4):e59787
pubmed: 23585827
J Infect Dis. 2013 Nov 1;208(9):1459-63
pubmed: 23904291
J Infect Dis. 2013 Nov 15;208(10):1624-8
pubmed: 23908493
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4
pubmed: 24442233
BMC Health Serv Res. 2014 Mar 07;14:116
pubmed: 24606875
PLoS One. 2014 Mar 07;9(6):e90845
pubmed: 24609015
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
PLoS One. 2014 Oct 30;9(10):e109296
pubmed: 25357201
AIDS Res Hum Retroviruses. 2015 Mar;31(3):347-52
pubmed: 25517728
PLoS Pathog. 2015 Mar 23;11(3):e1004722
pubmed: 25798934
PLoS Med. 2015 Apr 07;12(4):e1001810
pubmed: 25849352
Virol J. 2015 Feb 13;12:24
pubmed: 25889106
Lancet HIV. 2014 Nov;1(2):e58-9
pubmed: 26423988
Nucleic Acids Res. 2016 Jan 4;44(D1):D67-72
pubmed: 26590407
AIDS Res Hum Retroviruses. 2016 Aug;32(8):763-9
pubmed: 27002368
J Antimicrob Chemother. 2017 Jan;72(1):210-219
pubmed: 27659733
AIDS. 2016 Nov 13;30(17):2685-2695
pubmed: 27782965
PLoS One. 2016 Dec 1;11(12):e0166305
pubmed: 27907009
Curr Opin HIV AIDS. 2017 Mar;12(2):117-122
pubmed: 28134712
J Infect Dis. 2017 May 1;215(9):1362-1365
pubmed: 28329236
EBioMedicine. 2017 Apr;18:225-235
pubmed: 28365230
Virus Evol. 2017 Apr 19;3(1):vex008
pubmed: 28458918
AIDS Res Hum Retroviruses. 2017 Dec;33(12):1181-1184
pubmed: 28793781
AIDS. 2017 Aug 28;31(17):2387-2391
pubmed: 28857824
J Infect Dis. 2017 Dec 1;216(suppl_9):S824-S828
pubmed: 29040621
Lancet HIV. 2018 Mar;5(3):e146-e154
pubmed: 29174084
AIDS. 2018 Jan 28;32(3):363-369
pubmed: 29194115
Lancet Infect Dis. 2018 Mar;18(3):346-355
pubmed: 29198909
PLoS Pathog. 2018 Feb 20;14(2):e1006895
pubmed: 29462208
AIDS. 2018 Jul 17;32(11):1543-1546
pubmed: 29762166
Lancet HIV. 2018 Jul;5(7):e400-e404
pubmed: 29884404
N Engl J Med. 2018 Sep 6;379(10):979-981
pubmed: 30037297
South Afr J HIV Med. 2018 Oct 04;19(1):796
pubmed: 30349742
AIDS Res Hum Retroviruses. 2019 Feb;35(2):129-138
pubmed: 30430843
Lancet HIV. 2019 Feb;6(2):e116-e127
pubmed: 30503325
J Virus Erad. 2018 Nov 15;4(Suppl 2):55-58
pubmed: 30515315
AIDS Behav. 2018 Dec 6;:
pubmed: 30523490